$SRPT Sarepta Therapeutics is down because the FDA notice on the golodirsen CRL. The DMD drug maker will shake out bulls today. What will the stock close at in a week?Down? Agree on more losses ahead.Up? Disagree.SRPT is $98 in pre-market: $SRPT, Sarepta Therapeutics, Inc. / H1